NRG Oncology trial RTOG 9813 determined that MGMT promoter methylation was an independent predictor of overall survival for patients with anaplastic astrocytoma, a type of malignant brain tumor. The abstract “MGMT Promoter Status Independently Predicts Overall Survival in Anaplastic Astrocytoma in NRG Oncology/RTOG 9813: A Phase III Trial of Radiation Plus Nitrosourea Versus Radiation Plus Temozolomide” was presented at the American Society for Radiation Oncology (ASTRO) 59th Annual Meeting in San Diego, California and was also a recipient of a “Best of ASTRO” award for 2017. Read the full press release